BUZZ-SciSparc jumps as unit files patent for obesity, fatty liver treatment
Reuters03-12
BUZZ-SciSparc jumps as unit files patent for obesity, fatty liver treatment
** Shares of Israel-based drug developer SciSparc SPRC.Osurge 34% to $5.21 premarket
** Co says its majority-owned unit NeuroThera Labs filed an international patent for a new combination drug aimed at obesity and metabolic liver disease
** Treatment combines MEAI and PEA, developed with Clearmind MedicineCMND.O, co says
** Targets obesity and MASLD, a condition where excess fat builds up in the liver and disrupts metabolism; MASLD was earlier known as fatty liver disease - SPRC
** Co says therapy could be a safer, cheaper alternative to GLP-1 weight-loss drugs, which can cause side effects
** Shares up ~82% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments